Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases.

Citation: Gavai AV, Fink BE, Fairfax DJ, Martin GS, Rossiter LM, Holst CL, Kim SH, Leavitt KJ, Mastalerz H, Han WC, Norris D, Goyal B, Swaminathan S, Patel B, Mathur A, Vyas DM, Tokarski JS, Yu C, Oppenheimer S, Zhang H, Marathe P, Fargnoli J, Lee FY, Wong TW, Vite GD.: Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases. J Med Chem, Volume 52 (21), 2009
Authors: Fairfax DJ, Fargnoli J, Fink BE, Gavai AV, Goyal B, Han WC, Holst CL, Kim SH, Leavitt KJ, Lee FY, Marathe P, Martin GS, Mastalerz H, Mathur A, Norris D, Oppenheimer S, Patel B, Rossiter LM, Swaminathan S, Tokarski JS, Vite GD., Vyas DM, Wong TW, Yu C, Zhang H
Journal: J Med Chem
Year: 2009
DOI: 10.1021/jm9010065
PubMed: 19821562
Machine-readable: REST API RDF

Publication